AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02271061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
Study NCT02271061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control tape
Description: Apply tape in same technique without tension.
Study NCT01830985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
Study NCT01265017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol, medroxyprogesterone, hydrocortisone, GH
Description: * Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,
Study NCT01265017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: matching placebo
Study NCT01952938 — intervention group
Intervention type: PROCEDURE
Intervention: LINK SL versus EnduRo
Study NCT02252315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Brochure
Description: Participants will receive written education materials about mild traumatic brain injury.
Study NCT02252315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal education module
Description: A structured in-person education module about mild traumatic brain injury.
Study NCT03539757 — intervention group
Intervention type: DEVICE
Intervention: Non-Contrast Magnetic Resonance Imaging
Description: The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
Study NCT01583673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Formula
Description: Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
Study NCT01583673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid formula
Description: Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
Study NCT03886467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based nutrition education
Description: Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
Study NCT01293812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 88% sucrose po solution
Description: 88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated).
Study NCT01293812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo po
Description: The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated).
Study NCT03361215 — intervention group
Intervention type: OTHER
Intervention: Biosampling for molecular analysis
Description: Observational study with no therapeutic intervention. Biosampling for molecular analysis
Study NCT01663311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medial Frontal rTMS Double-Cone-Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
Study NCT01663311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left DLPFC Butterfly Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
Study NCT02708680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: An orally available histone deacetylases inhibitor (HDAC).
Study NCT02708680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
Study NCT02708680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
Study NCT02708680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill containing no active drug ingredient
Study NCT01634217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iTreg
Description: The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
Study NCT03179436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
Study NCT03179436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
Study NCT02935166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
Study NCT02935166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory muscle training
Description: General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
Study NCT00003748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
Study NCT03499418 — intervention group
Intervention type: OTHER
Intervention: modified Silverman scale
Description: Clinical assessment of severity of respiratory failure
Study NCT03499418 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiographic evaluation of haemodynamic problems
Study NCT01649466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAF237
Description: Vildagliptin will be used as commercially available tablets of 50mg.
Study NCT01649466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protaphane
Description: Protaphane will be used as commercially available injection pens
Study NCT04183647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration / local vibration
Description: Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.
Study NCT03489161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
Study NCT04001920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: 12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
Study NCT04551911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rayaldee
Description: 30 mcg calcifediol Extended-Release (ER) Capsule
Study NCT04551911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg calcifediol Extended-Release (ER) Capsule
Study NCT03801538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa
Description: Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
Study NCT02304679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 weekly LIESWT (Wave 1) with the RENOVA device
Description: Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Study NCT02304679 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 4 weekly sham LIESWT (Wave 1) with the RENOVA device
Description: Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires 1 month after Wave 1
Description: (Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Study NCT03801538 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside Analog (Substance)
Description: Patients do not need to change their NAs treatment.
Study NCT04180553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point of Care Ultrasound (POCUS)
Description: The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP \<90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
Study NCT04180553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
Study NCT00225121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: investigational drug by oral route (escalating doses depending on safety) administered until progression
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up questionnaires 1 month after Wave 1
Description: (Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires 3 months after Wave 1
Description: (Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up questionnaires 3 months after Wave 1
Description: (Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit.
Study NCT02304679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 bi-weekly LIESWT (Wave 2) with the RENOVA device
Description: During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Study NCT02304679 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 8 bi-weekly LIESWT (Wave 2) with the RENOVA device
Description: During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires 1 month after Wave 2
Description: (Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up questionnaires 1 month after Wave 2
Description: (Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires via postal mail
Description: Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires via postal mail
Description: Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Final follow-up questionnaires 12 months after Wave 2
Description: (Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Study NCT02304679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Final follow-up questionnaires 12 months after Wave 2
Description: (Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Study NCT00569881 — intervention group
Intervention type: DRUG
Intervention: gatifloxacin and moxifloxacin
Description: Comparison of wound healing between drugs
Study NCT02859948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
Study NCT01207505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Emotion Regulation
Description: 12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
Study NCT00725530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A contact lens (PureVision)
Description: Commercially marketed, silicone hydrogel contact lens
Study NCT00725530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A contact lens (Acuvue2)
Description: Commercially marketed, hydrogel contact lens
Study NCT02384941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily, before first meal of the day.
Study NCT02384941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo once daily, before first meal of the day.
Study NCT02384941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin once daily, before first meal of the day.
Study NCT01066949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral self mangement
Description: Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
Study NCT01066949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support and discussion
Description: Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
Study NCT00865618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg Tablets Sandoz Inc., USA
Study NCT00865618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inspra 50 mg Tablets GD Searle LLC, USA
Study NCT02107326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Webdia Software
Study NCT00988689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: soup with or without starch